Newsletter Subject

IL-13 Receptors: Therapeutic Targets for Inflammatory Diseases and Cancer

From

newscientist.com

Email Address

NewScientist@e.newscientist.com

Sent On

Mon, Jul 11, 2022 06:15 PM

Email Preheader Text

Every now and then, New Scientist helps a carefully selected commercial partner speak to our audienc

[NS Logo]( [Sino Biological Logo]( Every now and then, New Scientist helps a carefully selected commercial partner speak to our audience. Their support helps us produce the high quality journalism we bring you every week. We hope you find today's message relevant and useful. [Sino Biological]( [IL-13 Receptors]( [Sino Biological]( [Featured Products]( [Featured Cytokines]( [CRO Services]( IL-13 receptors, including [IL13RA1]( [IL13RA2]( and [IL4R]( subunits, are components of the [IL-4]( [IL-13]( signaling pathways. They are associated with the pathogenesis and therapeutic development of cancer, asthma, and allergic diseases. As a glioma-restricted cell-surface epitope, IL13RA2 is being evaluated clinically as a potential cancer vaccine and CAR-T therapy target. The IL-13 receptors can be functionally classified into two types: shared and private. The shared IL-13 receptor is comprised of IL13RA1 and IL4R. IL-13 can also bind to the private IL-13 receptor, IL13RA2. IL13RA1 serves as the primary IL13-binding subunit of the IL-13 receptors. IL13RA2 can block IL-13-induced [STAT6]( signaling by acting as a decoy receptor with higher affinity. Overexpression of IL-13RA2, induced by [TNF-alpha]( and IL-13 signaling, can contribute to pro-fibrotic effects by activating AP-1 signaling and the production of [TGF beta](. IL-4R can also complex with the common gamma chain ( [γc/IL2RG]( to mediate the signaling of IL-4. Sino Biological has developed an array of high-quality Proteins, Antibodies, Genes, Lysate, and qPCR Primer pairs to support the study of IL-13 Receptors in understanding the immune response against neoplastic and inflammatory diseases. • From various species such as Human, Mouse, Canine, Rat, and Cynomolgus • High activity, High purity • Validated in Neutralization ELISA, WB, IF, and ICC • Rabbit MAb & PAb, Mouse MAb Featured IL-13 Receptor Proteins Cynomolgus IL13RA1 Protein | [90864-C08H]( [90864-C08H]( Immobilized Human IL-13 Protein (Cat#: [10369-H01H]( can bind Cynomolgus IL13RA1 Protein Cynomolgus IL4R Protein | [90897-C02H]( [90897-C02H]( Ability to inhibit IL-4 dependent proliferation of TF-1 human erthroleukemic cells Mouse IL13RA2 Protein | [50061-M38H]( [50061-M38H]( Immobilized mouse IL13RA2 can bind IL13/Biotin (Cat#: [10369-HNAC]( [50061-M38H]( Ability to inhibit mouse IL13-dependent proliferation of TF-1 human erythroleukemic cells [Sino Biological]( U.S.A Sino Biological US Inc. order_us@sinobiologicalus.com Europe Sino Biological Europe GmbH order_eu@sinobiologicaleu.com Global Sino Biological, Inc. order@sinobiological.com * This email has been sent to {EMAIL} * [Unsubscribe]( from further emails relating to selected third party partners from New Scientist. * Read our [privacy policy]( [Contact Us]( Disclaimer This message is intended only for the use of the person(s) ("Intended Recipient") to whom it is addressed. It may contain information which is privileged and confidential. Accordingly any dissemination, distribution, copying or other use of this message or any of its content by any person other than the Intended Recipient may constitute a breach of civil or criminal law and is strictly prohibited. If you are not the Intended Recipient, please contact the sender as soon as possible. We and our third party service providers may use cookies and other web technologies in conjunction with this email. These technologies are used to understand activity with this email and on certain portions of our website. This enables us to improve our site, your experience on our site, and the offerings that we may provide to you. If you do not want these technologies placed on your device, please opt-out of receiving emails from us. Copyright New Scientist Registered Office: New Scientist, Northcliffe House, 2 Derry Street, Kensington, London, W8 5TT Registered in England under Company No. 10644366 Australian mailing address: PO Box 2315, Strawberry Hills, NSW 2012, Australia Registered in Australia under ABN 22 621 413 170

Marketing emails from newscientist.com

View More
Sent On

30/08/2024

Sent On

30/08/2024

Sent On

29/07/2024

Sent On

01/07/2024

Sent On

10/06/2024

Sent On

20/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.